CSIMarket
 


Cytokinetics Incorporated  (CYTK)
Other Ticker:  
 


Cytokinetics Incorporated's ROI from its third quarter of 2023 to the third quarter of 2022 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Cytokinetics Incorporated's ROI in the third quarter of 2023?
Cytokinetics Incorporated recorded a cumulative net loss of $-527 million during 12 months ending in the third quarter of 2023, resulting in a negative return on investment (ROI) of -67.49%.

Within the Healthcare sector 675 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2023 quarter, so far to 4023, from total ROI ranking in the second quarter of 2023 at 4215.

Definition and Formula of Return on Investment


Return On Investment (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Investment Change -33.68 % 1.33 % 3.19 % 20.88 % -
Y / Y Net Income Change - - - - -
Investment (TTM) in Millions 663 714 815 930 999
Return On Investment (TTM) -67.49 % -62.41 % -49.96 % -45.44 % -34.59 %
CYTK's Overall Ranking # 4023 # 4215 # 4100 # 4057 # 0
Seq. Investment Change -7.19 % -12.31 % -12.42 % -6.93 % 41.79 %
Seq. Net Income Change - - - - -
Net Income (TTM) in Millions -527 -540 -431 -389 -282




Return On Investment CYTK's Ranking
Within: No.
Industry # 297
Sector # 676
Overall # 4023

Return On Investment Statistics
High Average Low
20.6 %
-36.71 %
-67.49 %
(Dec 31 2016)   (Sep 30 2023)



  News about Cytokinetics Incorporated

Cytokinetics Unites with Global Organizations to Advocate for Rare Diseases Amidst Challenging Financial Climate



Cytokinetics, Incorporated, a biopharmaceutical company, recently announced its partnership with the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) in support of Rare Disease Day. This international campaign aims to increase awareness and public understanding of rare diseases, highlighting the challenges faced by over 300 million people living with such conditions worldwide. Additionally, Cytokinetics' financial performance has been notably affected, as the company recorded a cumulative net loss of $527 million during the 12-month period ending in the third quarter of 2023, contributing to a negative return on investment (ROI) of -67.49%.
Cytokinetics' Commitment to Rare Disease Day:
Cytokinetics' decision to join the EURORDIS and NORD in recognizing Rare Disease Day demonstrates the company's dedication to raising awareness and promoting better access to diagnosis, treatment, care, and social opportunities for individuals with rare diseases. By participating in this global initiative, Cytokinetics aims to contribute to a more equitable healthcare landscape and improve the lives of millions of people affected by rare diseases.